## Thomas M Elliott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6081724/publications.pdf

Version: 2024-02-01

759233 888059 19 331 12 17 citations h-index g-index papers 20 20 20 632 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Unexpected benefit of COVID-19 hospital restrictions: Reduction in patients isolating with multidrug resistant organisms after restrictions were lifted. Infection, Disease and Health, 2022, 27, 10-14.	1.1	4
2	Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021. International Journal of Environmental Research and Public Health, 2022, 19, 3178.	2.6	22
3	Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. Prostate Cancer and Prostatic Diseases, 2021, 24, 169-176.	3.9	24
4	Evaluating the economic effects of genomic sequencing of pathogens to prioritise hospital patients competing for isolation beds. Australian Health Review, 2021, 45, 59.	1.1	5
5	Budget impact analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia. BMJ Open, 2021, 11, e041968.	1.9	28
6	Healthcare costs of investigations for stillbirth from a population-based study in Australia. Australian Health Review, 2021, , .	1.1	4
7	Cost-effectiveness analysis of whole-genome sequencing during an outbreak of carbapenem-resistant $<$ i> Acinetobacter baumannii $<$ i> Antimicrobial Stewardship & Healthcare Epidemiology, 2021, 1, .	0.5	5
8	Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia. Value in Health, 2020, 23, 994-1002.	0.3	10
9	Estimating the costs of genomic sequencing in cancer control. BMC Health Services Research, 2020, 20, 492.	2.2	18
10	A hybrid simulation model approach to examine bacterial genome sequencing during a hospital outbreak. BMC Infectious Diseases, 2020, 20, 72.	2.9	16
11	The Economic Impact on Australian Patients with Neuroendocrine Tumours. Patient, 2020, 13, 363-373.	2.7	11
12	Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer. Clinical and Experimental Metastasis, 2020, 37, 305-312.	3.3	28
13	Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study. BMJ Open, 2020, 10, e034388.	1.9	18
14	Evaluating a risk assessment tool to improve triaging of patients to colonoscopies. Internal Medicine Journal, 2019, 49, 1292-1299.	0.8	2
15	Multiplicity of skin cancers in Queensland and their cost burden to government and patients. Australian and New Zealand Journal of Public Health, 2018, 42, 86-91.	1.8	20
16	Coaching Patients Saves Lives and Money. American Journal of Medicine, 2018, 131, 415-421.e1.	1.5	17
17	Patient out-of-pocket medical expenses over 2 years among Queenslanders with and without a major cancer. Australian Journal of Primary Health, 2018, 24, 530.	0.9	17
18	Outâ€ofâ€pocket medical expenses for Queenslanders with a major cancer. Medical Journal of Australia, 2018, 208, 497-497.	1.7	13

## THOMAS M ELLIOTT

#	Article	IF	CITATIONS
19	Estimated Healthcare Costs of Melanoma in Australia Over 3ÂYears Post-Diagnosis. Applied Health Economics and Health Policy, 2017, 15, 805-816.	2.1	64